TABLE 3

Multivariate logistic regression for predictors of loss to follow-up in Namibia

CovariatesaOR (95% CI)p-value
MTP for TB
 MTP period I0.5 (0.30–0.96)0.037*
 MTP period II1
Region
 Karas18.8 (4.9–73)0.001*
 Otjozondjupa3.9 (1.0–15.6)0.001*
 Kunene3.2 (1.0– 4.1)0.048*
 Khomas1.7 (0.13–23)0.043*
 Kavango West1.4 (0.5–4.0)0.681
 Zambezi1.4 (0.5–4.0)0.491
 Erongo0.4 (0.04–3.8)0.443
 Hardap0 (0–10.4)0.430
 Ohangwena0.6 (0.1–7.3)1.000
 Omaheke1.6 (0.4–2.1)0.641
 Oshikoto0 (0)0.499
 Oshana0.7 (0.7)0.999
 Kavango East10.537
Patient sex
 Male2.2 (1.3–3.8)0.004*
 Female1
Patient age years
 0–40 (0–451)0.025*
 5–1414.4 (0.5–281)1.000
 15–2429.7 (3.1–194)0.128
 25–3421.6 (2.4–110)0.003*
 35–4412.2 (1.4–109)0.006*
 45–5411.5 (1.2–71.6)0.025*
 55–646.2 (0.6–0.8)0.033*
 ≥6510.140
DOTS regimen
 2 RHZE/4 RHE1.0 (0.6–1.9)0.748
 Other regimens1
DOTS provider
 Guardian1.0 (0.3–4.0)0.001*
 Workplace0.8 (0.03–26.8)0.886
 Health facility0.3 (0.08–1.2)0.921
 Community health worker0 (0)0.085
 Other DOTS providers10.999
2 month's sputum conversion
 Smear negative1.6 (0.9–3.2)0.047*
 Smear positive0.4 (0.2–1.2)0.113
 Smear not assessed10.116
Anti-retroviral treatment
 No1.9 (0.9–3.9)0.052
 Yes1
HIV status
 Negative0.8 (0.2–3.0)0.474
 Positive1.5 (0.4–6.2)0.776
 Unknown10.563
Facility level
 Hospital0.6 (0.2–1.9)0.511
 PHC clinic0.6 (0.3–1.4)0.437
 Health centre10.247
Constant00.006

aOR: adjusted odds ratio; MTP: medium-term plan; TB: tuberculosis; DOTS: directly observed treatment, short-course; RHZE: rifampicin/isoniazid/pyrazinamide/ethambutol; RHE: rifampicin/isoniazid/ethambutol; PHC: primary healthcare. *: p<0.05.